Conditions: Colitis, Ulcerative
Keywords: Rebamipide Enema Ulcerative Colitis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 124
Healthy volunteers: no

Brief summary:
The purpose of this study is to examine the safety and efficacy of rebamipide by once daily intracolonial administration at 0 (placebo), 60, 150, or 300 mg for 6 weeks in patients with active ulcerative colitis, who are being treated with oral aminosalicylic acid (ASA).

Detailed description:

Arms:
arm 1: 0mg rebamipide arm 2: 60mg rebamipide arm 3: 150mg rebamipide arm 4: 300mg rebamipide

Interventions: intervention 1: rebamipide
Intervention descriptions: intervention 1: 0, 60, 150, 300mg of rebamipide per day for 6 weeks into colon

Protocol document: